UPCOMING EVENT Decoding Clinical Trials: Data, Decisions, and Deals in Big Pharma R&D
Virtual
Wednesday, October 4 at 1 p.m. ET
Register Now
When a biotech releases new results, there's often a flurry of speculation about whether a deal or buyout will follow. But what does it really take for big pharma to think it's worth investing in an R&D program?
Host Dr. Frank David will speak with Paul Lyne, Ph.D., senior vice president and head of research unit oncology at EMD Serono, about how large drugmakers decide if data are strong enough to move forward and the ways that R&D-stage biotechs miss the mark.
No comments